Compare SYRE & STAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | STAG |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.3B |
| IPO Year | 2015 | 2010 |
| Metric | SYRE | STAG |
|---|---|---|
| Price | $86.72 | $37.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 9 |
| Target Price | ★ $85.08 | $39.67 |
| AVG Volume (30 Days) | 892.9K | ★ 1.1M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $845,184,000.00 |
| Revenue This Year | N/A | $8.59 |
| Revenue Next Year | N/A | $9.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.14 |
| 52 Week Low | $14.49 | $33.72 |
| 52 Week High | $88.03 | $39.99 |
| Indicator | SYRE | STAG |
|---|---|---|
| Relative Strength Index (RSI) | 67.73 | 48.65 |
| Support Level | $66.78 | $37.36 |
| Resistance Level | N/A | $38.72 |
| Average True Range (ATR) | 4.83 | 0.74 |
| MACD | 1.12 | 0.06 |
| Stochastic Oscillator | 82.70 | 54.80 |
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Stag Industrial Inc is a REIT focused on the acquisition, ownership, development, and operation of industrial properties throughout the United States. Its platform is designed to (i) identify properties for acquisition that offer attractive returns across CBRE-EA Tier 1 industrial real estate markets, industries, and tenants, (ii) provide growth through the ownership of high-quality assets, property management and pursuit of acquisitions in an attractive opportunity set, and (iii) capitalize its business appropriately given the characteristics of its assets. The majority of its portfolio is single-tenant industrial properties throughout the United States. The company derives the majority of its rental revenue from its facilities located in Midwestern and Eastern U.S. cities.